Detailed description page of SalivaDB

This page displays user query in tabular form.

SAL_16443 details
Primary information
SALIDSAL_16443
Biomarker nameECA
Biomarker TypeNA
Sampling MethodAlterations of salivary glycopatterns were probed using lectin microarrays and blotting analysis from 337 patients with breast benign cyst or tumor (BB) or breast cancer (I/II stage) and 110 healthy humans.
Collection MethodWhole saliva (about 1 mL) was collected and placed on ice.
Analysis MethodLectin blotting
Collection SiteWhole Saliva
Disease CategoryCancer
Disease/ConditionBreast Cancer
Disease SubtypeNA
Fold Change/ ConcentrationNA
Up/DownregulatedNA
ExosomalNA
OrganismHomo sapiens
PMID29402727
Year of Publication2018
Biomarker ID194301
Biomarker CategoryMetabolite
SequenceC1=CC(=C(C(=C1)O)O)C(=O)NCC2=CC(=CC(=C2)CNC(=O)C3=C(C(=CC=C3)O)O)CNC(=O)C4=C(C(=CC=C4)O)O
Title of studySalivary Glycopatterns as Potential Biomarkers for Screening of Early-Stage Breast Cancer
Abstract of studyOBJECTIVE: We systematically investigated and assessed the alterations of salivary glycopatterns and possibility as biomarkers for diagnosis of early-stage breast cancer.DESIGN: Alterations of salivary glycopatterns were probed using lectin microarrays and blotting analysis from 337 patients with breast benign cyst or tumor (BB) or breast cancer (I/II stage) and 110 healthy humans. Their diagnostic models were constructed by a logistic stepwise regression in the retrospective cohort. Then, the performance of the diagnostic models were assessed by ROC analysis in the validation cohort. Finally, a double-blind cohort was tested to confirm the application potential of the diagnostic models.RESULTS: The diagnostic models were constructed based on 9 candidate lectins (e.g., PHA-E+L, BS-I, and NPA) that exhibited significant alterations of salivary glycopatterns, which achieved better diagnostic powers with an AUC value >0.750 (p<0.001) for the diagnosis of BB (AUC: 0.752, sensitivity: 0.600, and specificity: 0.835) and I stage breast cancer (AUC: 0.755, sensitivity: 0.733, and specificity: 0.742) in the validation cohort. The diagnostic model of I stage breast cancer exhibited a high accuracy of 0.902 in double-blind cohort.CONCLUSIONS: This study could contribute to the screening for patients with early-stage breast cancer based on precise alterations of salivary glycopatterns.